Reports Q4 revenue $465M, consensus $465M. “Concentra (CON) had a successful 2024 – a year marked by change with our IPO and separation from Select Medical. We made significant progress on key strategic initiatives and maintained our emphasis on the delivery of high-quality patient care. Our ability to execute on our objectives and the tireless efforts of our colleagues contributed to our favorable 2024 financial outcomes. I am confident in our ability to continue to deliver strong results in 2025,” said Keith Newton, Chief Executive Officer of Concentra.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CON:
- CON Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Select Medical price target lowered to $23 from $47 at RBC Capital
- Benchmark upgrades Select Medical, sees attractive entry point after pullback
- Concentra Expands with Nova Medical Acquisition
- Concentra price target raised to $25 from $24 at BofA